A specialty pharma executive with proven track record of successfully launching major innovative products and extensive experience in directing all aspects of operations, incl. strategy, business planning, marketing & sales, P&L, market access and pricing

General Manager @ General Manager D-A-CH-CZ @ Build an organization in Central Europe to develop orphan drugs and commercialize innovative treatments for mitochondrial and neuromuscular diseases with high unmet medical need. Santhera has a late-stage development pipeline. The lead compound Raxone®/Catena® (INN: idebenone) is being developed in three indications: Leber's Hereditary Optic Neuropathy (LHON), Duchenne Muscular Dystrophy (DMD), and Primary Progressive Multiple Sclerosis (PPMS). From May 2015 to Present (6 months) Munich Area, GermanyGeneral Manager DACH @ • Focus on all aspects of building an ultra-rare disease franchise, incl. establishing a comprehensive disease awareness campaign for LAL-deficiency and a regional infrastructure to support product registration, launch and commercialization of an enzyme replacement therapy • Extensively engage with academia, physicians and patient advocacy to drive testing and identification of the patient population • Definition and execution of a market entry plan for the product candidates and a commercial plan for the orphan drug products with a focus on market access (G-BA assessment and reimbursement) From January 2014 to October 2014 (10 months) Munich Area, GermanyExecutive Director Biomarker/Diagnostics @ Business development responsibilities for pursuing strategic growth initiatives by steering biomarker and diagnostic development activities for Global Drug Discovery, development and commercialization. As member of the Corporate cross functional diagnostics and biomarker board, providing strategic guidance on opportunities for biomarker/diagnostic discovery and development. Focus is to build successful relations with diagnostics partners, ensure access of diagnostics and providing a comprehensive analysis of available partnering options to select the best possible partner and model for a relationship, i.e. research collaboration, license agreement, mergers and acquisitions, strategic affiliations, joint ventures, and other business partnerships. Ensure commercial implementation of the biomarker strategy. From March 2012 to November 2013 (1 year 9 months) Boudry/SwitzerlandGeneral Manager @ 2009 - 2012 General Manager Oversaw operations with 140 employees, directing local senior management team. Managed financial and business planning, market acess and pricing, forecast development and key opinion leader relationships. Created and conveyed affiliate strategy and vision. Provided leadership and support, participating in sales conferences, directing staff meetings and working with medical department leaders. Coached and mentored staff. Key Accomplishments: • Created highly productive, achievement-focused workplace, using collaborative leadership style to garner top ratings in Gallup employee survey and retain high-value employees. • Surpassed revenue and margin objectives, generating double-digit growth and securing fastest growing affiliate status in EU5 division with #1 performance in sales. • Developed new oncology business unit, successfully re-launched Abraxane in MBC. 2006 - 2008 Sales & Marketing Director Established new operations, including distribution and logistics workflows, KPI dashboards and business planning and forecasting procedures. Created and executed Revlimid launch in haematology market and managed additional high-profile product launch initiatives. Integrated acquired Pharmion business unit and sales team. Provided important strategic insights to executive council. Identified key opinion leaders and cultivated relationships to elevate product profiles and drive new business development. Skilfully managed brand. Key Accomplishments: • Used experience and skills to create organisation from the ground up, establishing local infrastructure, including patient programme and risk mitigation strategies. • Created and executed relationship management strategy, gaining key opinion leader, payer and patient advocacy group trust. • Secured marketplace leadership within 2 years with launch of Revlimid and rolled out Thalidomide and Vidaza products successfully. From March 2006 to March 2012 (6 years 1 month) MunichManager Distributor Commercial Operations @ Led hospital business spinoff project, overseeing portfolio that included critical care, infusion, pain management, venipuncture and generic products. Designed and implemented operational infrastructure, developed business model and created and implemented growth strategy. Formulated distribution plan for 10 countries. Selected partners and negotiated contracts. Key Accomplishments: • Achieved successful spinoff with detailed planning, making long and short-term goals, delivering project components and rolling out regional operations on time. • Established robust distribution network, analysing candidates and selecting and contracting partners to meet organisational objectives. From May 2004 to April 2006 (2 years) Amsterdam / WiesbadenBusiness Unit Manager Oncology + Hematology @ Led business units and managed broad hem-onc product portfolio, overseeing a team of up to 60. Managed P&L for €70m business unit, generating double-digit growth rates and achieved market leadership for IntronA. Led restructurings and directed key projects and programmes, including marketing, launches, business development, imports, CRM and promotions. Made key strategy decisions and created business plans. Key Accomplishments: • Successfully launched Temodal,Caelyx and PegIntron and worked with Grunenthal to rollout Transtec in Oncology. • Secured endorsement of high-dose interferon therapy for treatment of melanoma from German Dermatology Association. • Outperformed sales targets and played an integral role in establishing high-profile investigator initiated trials involving numerous stakeholders. From December 1998 to September 2003 (4 years 10 months) European Business Unit Manager Immunotherapy @ Directed sales, budget and P&L responsibility for several medical device product lines for sampling, purging / immunoselection and cryopreservation of human bone marrow or peripheral blood. In-licensed and successfully launched a diagnostic kit in Breast Cancer. Led a remote European sales and medical liason team. Established a cross-functional network of technicians, specialists and sales managers to service transplant units and blood banks. Key Accomplishments: • Tripled sales in 5 years, accomplished market leadership in the selection market and break even on an divisional level. • Managing transition of immunoselection business to a joint venture partner NEXELL Therapeutics, CA, U.S.A. 1993 - 1997 European Product Manager Immunotherapy From July 1993 to November 1998 (5 years 5 months) MunichSales Rep @ From 1991 to 1993 (2 years)

MBA, Economics @ Universität zu Köln / University of Cologne From 1991 to 2004 PhD, Plant Biochemistry @ Technische Universität München / Technical University of Munich From 1986 to 1991 Diploma, Biology & Chemistry @ Universität zu Köln / University of Cologne From 1979 to 1987 Robert Schupp is skilled in: Oncology, Hematology, Product Launch, Pharmaceutical Industry, Lifesciences, Biotechnology, Commercialization, Biopharmaceuticals, Clinical Development, Cross-functional Team..., Market Access, Clinical Trials, Strategy, Drug Discovery, Biomarkers, Medical Devices, Pharmaceutical Sales, Sales Effectiveness, Pharmaceutics, Hardware Diagnostics, Mergers & Acquisitions, Global Marketing, Validation, Immunology, Clinical Research, Marketing Communications, Hospital Sales, Diabetes, Dermatology, FDA, CRO, Sop, Medical Affairs, Mergers, GCP, Technology Transfer, Drug Development, Regulatory Affairs, Vaccines, Competitive Intelligence, Pharmacovigilance, Infectious Diseases, CTMS, Regulatory Submissions, GMP, Neurology, Regulatory Requirements, Orphan Drugs, Rare Diseases, Life Sciences